Adults 18 and older with obstructive sleep apnea (OSA) and overweight or obesity may qualify for a clinical study evaluating an investigational once-weekly medication designed to support weight reduction and improve sleep-related breathing.
Obstructive Sleep Apnea and Obesity
Age Range:
18
Gender:
Male and Female
Location:
Buffalo, New York
About the Study
This research study is evaluating an investigational medication administered once weekly by injection, to determine whether it can help reduce body weight and improve OSA severity.
Researchers will compare the investigational medicine to a placebo* to assess its effects on breathing disruptions during sleep, weight loss, and overall health outcomes. The study will also evaluate the safety and tolerability of the investigational treatment.
Participants may receive study-related care, including lifestyle counseling focused on nutrition and physical activity, as well as regular monitoring throughout the study.
* A placebo is a “fake” treatment—such as a sugar pill, injection, or procedure—that contains no active medicine or therapeutic value. It is designed to look exactly like a real treatment but is used to test the effectiveness of an investigational medicine in research studies.
Qualifications
You may qualify if you:
- Are 18 years of age or older.
- Have a diagnosis of moderate-to-severe obstructive sleep apnea.
- Do not have diabetes.
- Have overweight or obesity (BMI ≥27 kg/m²).
- Are either unable/unwilling to use PAP therapy or are currently using PAP therapy and plan to continue.
- Do not have certain sleep-related breathing disorders other than obstructive sleep apnea.
- Do not have significant or unstable medical conditions (such as recent cardiovascular events, severe kidney or liver disease, or uncontrolled endocrine disorders).
- Are not pregnant or breastfeeding.
FEATURED STUDIES
Researchers are studying an investigational medication to see how effective it may be as a potential weight reduction treatment. If […]
Adults 18 years and older may qualify for a study evaluating investigational treatment options for diabetic peripheral neuropathic pain (DPNP), […]
Adults 18 years and older may qualify for a study evaluating an investigational oral study medication for elevated lipoprotein(a) [Lp(a)], […]
Adults living with obesity or overweight who do not have type 2 diabetes may qualify for a research study evaluating […]
Adults living with obesity or overweight who do not have type 2 diabetes may qualify for a research study evaluating […]
Adults who are overweight or obese and currently using semaglutide (Ozempic®/Wegovy®) or tirzepatide (Mounjaro®/Zepbound®) may qualify for a research study […]